Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 44 clinical trials
Pharmacokinetics of Apixaban in Patients With Short Bowel Syndrome Requiring Long Term Parenteral Nutrition (ABSORB)

resection. It remains unclear to what extent apixaban exposure is impacted in SBS.Therefore this study tries to investigate the pharmacokinetics (PK) of apixaban in adult patients with SBS requiring long

Accepts healthy volunteers
  • 2 views
  • 07 Oct, 2022
  • 1 location
Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices (DOAC LVAD)

Prospective, randomized, controlled, open label, trial of LVAD patients with 1:1 randomization to either apixaban or warfarin.

warfarin
  • 0 views
  • 13 Mar, 2022
  • 1 location
  • 0 views
  • 21 Oct, 2022
  • 24 locations
Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter Study (API-AHAI)

decrease VTE from 50% to 10-15%. In certain high-risk medical situations, prolonged prophylaxis with apixaban has been shown to decrease the occurrence of VTE from 10.2% to 4.2% in solid cancers4 and from

cancer
  • 0 views
  • 04 Oct, 2022
  • 1 location
Avoiding Anticoagulation After IntraCerebral Haemorrhage

Randomised controlled trials (RCTs) demonstrate a substantial benefit from oral anticoagulant drugs for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation (AF). However, these RCTs excluded patients with prior intracerebral haemorrhage (ICH). Therefore, guidelines are unable to recommend whether oral anticoagulant drugs, in particular non-vitamin K antagonist …

electrocardiogram
anticoagulation therapy
brain ct
intracerebral hemorrhage
vitamin k antagonist
  • 0 views
  • 25 Jan, 2021
  • 2 locations
Mechanisms of Deep Vein Thrombosis (DVT) and Vein Wall Fibrosis

The goal of this study is to determine the safety and tolerability or efficacy of adjunctive treatments (including rosuvastatin 20 mg daily) in combination with standard anticoagulation therapy (Factor Xa inhibitors) in patients with lower extremity deep vein thrombosis (DVT). The efficacy of adjunctive treatments to prevent the development of …

  • 0 views
  • 22 Oct, 2021
  • 1 location
Vagus Nerve-guided Robotic-assisted Splenectomy and Azygoportal Disconnection (VNRSD)

This study aimed to evaluate whether vagus nerve-guided robotic-assisted splenectomy and azygoportal disconnection is effective and safe, and to determine whether a reduction in the incidence of postoperative complications of the digestive system improves postoperative quality of life compared with conventional robotic-assisted splenectomy and azygoportal disconnection.

splenectomy
hypertension
  • 0 views
  • 11 May, 2022
  • 1 location
Effects of Edoxaban on Platelet Aggregation

Rationale: The interaction between nonvitamin K oral anticoagulants (NOACs) and platelet aggregation is complex. The direct activated factor X inhibitors (factor Xa inhibitors) an NOAC antagonizes thrombin generation, one of most important platelet agonist, so that, factor Xa inhibitors has a potential effect in decreasing thrombin-mediated platelet aggregation. On the …

antiplatelet agents
coronary angioplasty
aspirin
antiplatelet therapy
stroke
  • 0 views
  • 22 Nov, 2021
  • 1 location
Sub-Clinical Atrial Fibrillation Biomarker Study (SCAF-b)

This is a sub-study of the ARTESiA study registered as NCT01938248. This study is designed to validate biomarkers in subclinical atrial fibrillation and to determine if the prospective biomarker will be informative of the potential efficacy of treatment.

  • 8 views
  • 14 Jun, 2022
  • 1 location
A Multi-center Observative Study of Apixaban After Left Atrial Appendage Occlusion in Patients With Non-valvular Atrial Fibrillation

The aim of the study is to enroll approximately 200 cases from 10 research centers nationwide, completed left atrial appendage occlusion (LAAO) successfully, and give apixaban (5 mg bid

Accepts healthy volunteers
  • 0 views
  • 21 Oct, 2022
  • 1 location